Sanofi supera las estimaciones de ingresos y resultados; eleva las perspectivas para el año fiscal 2026

Resumen del corpus

Sanofi surpassed income and results estimates, raising prospects for fiscal year 2026. The GAAP EPS for the third quarter reached €3.55, exceeding estimates by €2.04. Revenues of €14.44 billion (a 16.2% year-over-year increase) surpassed expectations, driven by a 31.4% rise in pharmaceutical sales, led by products like ALTUVIIIO, Ayvakit, and Rezurock. Sales of Dupixent increased by 34.8% to €5.7 billion, exceeding the €5 billion quarterly benchmark.